SeaSpine Announces Full Commercial Launch of Mariner Posterior Fixation System
July 07 2017 - 9:29AM
SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical
technology company focused on surgical solutions for the treatment
of spinal disorders, today announced the full commercial launch of
Mariner® Posterior Fixation System.
The Mariner Posterior Fixation System is a pedicle based system
featuring modular screw technology and accompanying
instrumentation. Designed to reduce the number of trays
needed for surgery, Mariner is intended to efficiently provide
surgeons with multiple intra-operative options to facilitate
posterior lumbar fixation. Mariner offers versatility and
adaptability by providing surgeons with a variety of instrument and
implant solutions for degenerative and complex spine pathologies,
including choices in rod diameter, rod material, construct
configuration, and deformity correction techniques. Key market
differentiators include in-situ modularity, motion limiting heads,
and rod versatility with both 5.5mm and 6.0mm offerings.
“In today’s hospital environment, the key is to have as many
options as you can for your patient without overburdening your
staff,” stated Douglas Orndorff, MD. “Mariner is versatile,
yet simple to use. Ultimately, it helps me make intraoperative
decisions seamlessly.”
Dr. Warren Yu, Director of Spine Surgery at George Washington
Hospital commented, “Mariner’s state-of-the-art instrumentation and
modular screw design provide me with the broad selection of implant
configurations that I need to address the challenging patient
anatomy I see in my adult spine practice – from basic degenerative
to complex deformity cases.”
“The Mariner Poster Fixation System brings innovative features
to the market and utilizes a modular design that increases surgeon
flexibility while reducing the number of trays that need to be
brought into the operating room,” stated Keith Valentine, Chief
Executive Officer of SeaSpine. “The Mariner launch is an important
enhancement to SeaSpine’s spinal hardware product offerings in the
$1.8 billion posterior lumbar fixation market.”
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology
company focused on the design, development and commercialization of
surgical solutions for the treatment of patients suffering from
spinal disorders. SeaSpine has a comprehensive portfolio of
orthobiologics and spinal hardware solutions to meet the varying
combinations of products that neurosurgeons and orthopedic spine
surgeons need to perform fusion procedures on the lumbar, thoracic
and cervical spine. SeaSpine’s orthobiologics products consist of a
broad range of advanced and traditional bone graft substitutes that
are designed to improve bone fusion rates following a wide range of
orthopedic surgeries, including spine, hip, and extremities
procedures. SeaSpine’s spinal hardware portfolio consists of an
extensive line of products to facilitate spinal fusion in minimally
invasive surgery (MIS), complex spine, deformity and degenerative
procedures. Expertise in both orthobiologic sciences and spinal
fusion hardware product development helps SeaSpine to offer its
surgeon customers a complete solution to meet their fusion
requirements. SeaSpine currently markets its products in the United
States and in over 30 countries worldwide.
Forward-Looking Statements
SeaSpine cautions you that statements included in this news
release that are not a description of historical facts are
forward-looking statements that are based on the Company's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements relating to: the design
benefits of the Mariner Posterior Fixation System, including its
potential to reduce the number of trays needed for surgery and
provide surgeons with multiple intra-operative options to
facilitate posterior lumbar fixation; and ability of the Mariner
Posterior Fixation System to complete in the $1.8 billion posterior
lumbar fixation market. Among the factors that could cause or
contribute to material differences between our actual results and
the expectations indicated by our forward-looking statements are
risks and uncertainties that include, but are not limited to: the
fact that the Mariner Posterior Fixation System has undergone only
limited clinical validation and may not address adequately surgeon
requirements; surgeons’ willingness to use the Mariner Posterior
Fixation System; the risk of supply shortages, including as a
result of our dependence on a limited number of third-party
suppliers for components and raw materials, or otherwise; and other
risks and uncertainties more fully described in our news releases
and periodic filings with the Securities and Exchange Commission.
The Company’s public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. SeaSpine
does not intend to revise or update any forward-looking statement
set forth in this news release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
Investor Relations Contact
Lynn Pieper
(415) 937-5402
ir@seaspine.com
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From Apr 2024 to May 2024
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From May 2023 to May 2024